Predictive value of CD4 cell count nadir on long-term mortality in HIV-positive patients in Uganda

FieldValue
dc.contributor.authorBray, S
dc.contributor.authorGedeon, J
dc.contributor.authorHadi, A
dc.contributor.authorKotb, A
dc.contributor.authorRahman, T
dc.contributor.authorSarwar, E
dc.contributor.authorSavelyeva, A
dc.contributor.authorSévigny, M
dc.contributor.authorBakanda, C
dc.contributor.authorBirungi, J
dc.contributor.authorChan, K
dc.contributor.authorYaya, S
dc.contributor.authorDeonandan, Raywat
dc.contributor.authorMills, E
dc.date.accessioned2012-08-20T14:17:39Z
dc.date.available2012-08-20T14:17:39Z
dc.date.created2012
dc.date.issued2012-08-20
dc.identifier.citationHIV/AIDS – Research and Palliative Care 2012:4, 135.140.
dc.identifier.urihttp://hdl.handle.net/10393/23159
dc.identifier.urihttp://www.dovepress.com/nbsppredictive-value-of-cd4-cell-count-nadir-on-long-term-mortality-in-peer-reviewed-article-HIV
dc.description.abstractObjective: Although international guidelines recommend initiating antiretroviral therapy (ART) when a patient’s CD4 cell count is #350 cells/µL, most patients in resource-limited settings present with much lower CD4 cell counts. The lowest level that their CD4 cell count reaches, the nadir, may have long-term consequences in terms of mortality. We examined this health state in a large cohort of HIV+patients in Uganda. // Design:This was an observational study of HIV patients in Uganda aged 14 years or older, who were enrolled in 10 major clinics across Uganda. // Methods: We assessed the CD4 nadir of patients, using their CD4 cell count at initiation of ART, stratified into categories (,50, 50–99, 100–149, 150–249, 250+cells/µL). We constructed Kaplan–Meier curves to assess the differences in survivorship for patients left-censored at 1 year and 2 years after treatment initiation. We used Cox proportional hazards regression to model the associations between CD4 nadir and mortality. We adjusted mortality for loss-to-follow-up. // Results: Of 22,315 patients, 20,129 patients had greater than 1 year of treatment follow-up. Among these patients, 327 (1.6%) died and 444 (2.2%) were lost to follow-up. After left-censoring at one year, relative to lowest CD4 strata, patients with higher CD4 counts had significantly lower rates of mortality (CD4 150–249, hazard ratio [HR] 0.60, 95% confidence interval [CI]: 0.45–0.82, P = 0.001; 250+, HR 0.66, 95% CI, 0.44–1.00, P = -0.05). Male sex, older age, and duration of time on ART were independently associated with mortality. When left-censoring at 2 years, CD4 nadir was no longer statistically significantly associated with mortality. // Conclusion: After surviving for 1 year on ART, a CD4 nadir was strongly predictive of longer-term mortality among patients in Uganda. This should argue for efforts to increase engagement with patients to ensure a higher CD4 nadir at initiation of treatment
dc.language.isoen
dc.subjectantiretroviral therapy
dc.subjectsub-Saharan Africa
dc.subjectprognosis
dc.subjectCD4
dc.subjectART
dc.titlePredictive value of CD4 cell count nadir on long-term mortality in HIV-positive patients in Uganda
dc.typeArticle
dc.identifier.doi10.2147/HIV.S35374
CollectionSciences de la santé - Publications // Health Sciences - Publications

Files